Morgan Stanley upgrades Johnson & Johnson, sees upside on robust drug pipeline
Morgan Stanley's price target implies that shares of Johnson & Johnson could rise another 17%.
Last updated: 2026-01-30 09:23:12 ET
No hourly mention data available.
Morgan Stanley's price target implies that shares of Johnson & Johnson could rise another 17%.
OpenAI’s latest funding round suggests a valuation of up to $830 billion, while Anthropic’s implies $350 billion
The company’s outlook implies revenue in the first quarter could be higher than what it was in the fourth quarter as a recovery takes hold.
Citi's $82 price target implies that shares of Dutch Bros could rally 34% from here.